Tong Y - Search Results

1

Pentamidine inhibits prostate cancer progression via selectively inducing mitochondrial DNA depletion and dysfunction.

Liu L, Wang F, Tong Y, Li LF, Liu Y, Gao WQ. Liu L, et al. Among authors: tong y. Cell Prolif. 2020 Jan;53(1):e12718. doi: 10.1111/cpr.12718. Epub 2019 Nov 13. Cell Prolif. 2020. PMID: 31721355 Free PMC article.

2

Proscillaridin A slows the prostate cancer progression through triggering the activation of endoplasmic reticulum stress.

Wang F, Liu L, Tong Y, Li L, Liu Y, Gao WQ. Wang F, et al. Among authors: tong y. Cell Cycle. 2020 Mar;19(5):541-550. doi: 10.1080/15384101.2020.1716484. Epub 2020 Feb 2. Cell Cycle. 2020. PMID: 32009541 Free PMC article.

3

Metabolic heterogeneity in cancer: An overview and therapeutic implications.

Tong Y, Gao WQ, Liu Y. Tong Y, et al. Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188421. doi: 10.1016/j.bbcan.2020.188421. Epub 2020 Aug 22. Biochim Biophys Acta Rev Cancer. 2020. PMID: 32835766 Review.

4

Inhibition of AMPK activity by TRIM11 facilitates cell survival of hepatocellular carcinoma under metabolic stress.

Liu Y, Xu Y, Wang F, Tong Y, Li H, Wan X, Yang X, Chen L. Liu Y, et al. Among authors: tong y. Clin Transl Med. 2021 Dec;11(12):e617. doi: 10.1002/ctm2.617. Clin Transl Med. 2021. PMID: 34919347 Free PMC article. No abstract available.

5

Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.

Tong Y, Wang F, Li S, Guo W, Li Q, Qian Y, Li L, Zhao H, Zhang Y, Gao WQ, Liu Y. Tong Y, et al. Hepatology. 2024 Jul 1;80(1):38-54. doi: 10.1097/HEP.0000000000000559. Epub 2023 Aug 9. Hepatology. 2024. PMID: 37556368

6

KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.

Guo W, Li S, Qian Y, Li L, Wang F, Tong Y, Li Q, Zhu Z, Gao WQ, Liu Y. Guo W, et al. Among authors: tong y. Clin Transl Med. 2023 Oct;13(10):e1452. doi: 10.1002/ctm2.1452. Clin Transl Med. 2023. PMID: 37846441 Free PMC article.

7

Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold.

Shan H, Ma X, Yan G, Luo M, Zhong X, Lan S, Yang J, Liu Y, Pu C, Tong Y, Li R. Shan H, et al. Among authors: tong y. Eur J Med Chem. 2021 Jul 5;219:113432. doi: 10.1016/j.ejmech.2021.113432. Epub 2021 Apr 3. Eur J Med Chem. 2021. PMID: 33857728

8

Design, synthesis and biological evaluation of 1H-indazole derivatives as novel ASK1 inhibitors.

Hou S, Yang X, Yang Y, Tong Y, Chen Q, Wan B, Wei R, Lu T, Chen Y, Hu Q. Hou S, et al. Among authors: tong y. Eur J Med Chem. 2021 Aug 5;220:113482. doi: 10.1016/j.ejmech.2021.113482. Epub 2021 Apr 20. Eur J Med Chem. 2021. PMID: 33906048

9

Novel Nonsecosteroidal Vitamin D Receptor Modulator Combined with Gemcitabine Enhances Pancreatic Cancer Therapy through Remodeling of the Tumor Microenvironment.

Kang Z, Wang C, Tong Y, Li Y, Gao Y, Hou S, Hao M, Han X, Wang B, Wang Q, Zhang C. Kang Z, et al. Among authors: tong y. J Med Chem. 2021 Jan 14;64(1):629-643. doi: 10.1021/acs.jmedchem.0c01197. Epub 2020 Dec 31. J Med Chem. 2021. PMID: 33381963

10

Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.

Pu C, Tong Y, Liu Y, Lan S, Wang S, Yan G, Zhang H, Luo D, Ma X, Yu S, Huang Q, Deng R, Li R. Pu C, et al. Among authors: tong y. Eur J Med Chem. 2022 Jun 5;236:114321. doi: 10.1016/j.ejmech.2022.114321. Epub 2022 Apr 3. Eur J Med Chem. 2022. PMID: 35430559

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,300 results

Search Page

Filters